Insilico Medicine Projects Triple-Digit Revenue Surge for Mid-2026

The company expects to report a net profit ranging from USD 33.5 million to USD 39.5 million for the six-month period ending June 30, 2026. Adjusted non-IFRS figures are projected to reach as high as USD 51.5 million. According to founder and Co-CEO Alex Zhavoronkov, this momentum stems from a robust expansion of global research collaborations and the successful deployment of proprietary AI platforms.

Central to this growth is the firm's strategic focus on out-licensing and co-development. During the first half of the year, Insilico secured new alliances with industry leaders including Eli Lilly, SK Biopharmaceuticals, and Saudi Aramco. These partnerships, alongside accelerated milestones within existing programs like those involving Menarini and Hisun Pharma, have solidified the company's revenue streams. Beyond commercial expansion, the firm continues to scale its technological infrastructure, notably through the launch of agentic systems such as PandaClaw and LabClaw. These tools are designed to automate biological analysis and laboratory orchestration, further integrating the company’s Pharma.AI ecosystem. With 31 nominated preclinical candidates and major clinical progress—including the Phase III advancement of Rentosertib—Insilico is positioning its AI-led discovery model as a sustainable engine for long-term drug development.